Vertex to Present at the J.P. Morgan Healthcare Conference on January 13
The audio portion of management’s remarks can be accessed live through Vertex’s website, www.vrtx.com, in the “Investors” section under the “News and Events” page. A replay of the conference webcast will be archived on the company’s website.
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney disease. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Founded in 1989 in
(VRTX-WEB)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005802/en/
Source:
Vertex Pharmaceuticals Incorporated
Investors:
Michael Partridge, 617-341-6108
Zach Barber, 617-341-6470
Leah Gibson, 617-961-1507